We are live on ! Find out more
BLRX

BioLineRX
BLRX

20 hedge funds and large institutions have $29.3M invested in BioLineRX in 2015 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

9% more capital invested

Capital invested by funds: $26.9M → $29.3M (+$2.35M)

20% less funds holding

Funds holding: 25 → 20 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
20
Holders Change
-5
Holders Change %
-20%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Senvest Management
New York
+$669K
2
Morgan Stanley
Morgan Stanley
New York
+$424K
3
Millennium Management
Millennium Management
New York
+$301K
4
NCCM
Nine Chapters Capital Management
New Jersey
+$269K
5
BCA
Benchmark Capital Advisors
New York
+$68.1K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$3.17M
2
SM
Sabby Management
Florida
-$1.57M
3
SFM
Sphera Funds Management
Israel
-$408K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$145K
5
Jane Street
Jane Street
New York
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$9.71M +$669K +540 +10%
BC
2
Broadfin Capital
New York
$8.25M – – –
O
3
OrbiMed
New York
$3.02M – – –
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$1.96M -$28.5K -23 -2%
Deutsche Bank
5
Deutsche Bank
Germany
$1.72M – – –
Millennium Management
6
Millennium Management
New York
$1.55M +$301K +243 +33%
Morgan Stanley
7
Morgan Stanley
New York
$1.46M +$424K +342 +60%
OM
8
Opaleye Management
Massachusetts
$495K – – –
NCCM
9
Nine Chapters Capital Management
New Jersey
$347K +$269K +217 New
BCA
10
Benchmark Capital Advisors
New York
$194K +$68.1K +55 +82%
MC
11
Menta Capital
California
$170K -$26K -21 -17%
VKH
12
Virtu KCG Holdings
New York
$154K +$59.4K +48 +98%
NFG
13
Next Financial Group
Texas
$99K – – –
Bank of New York Mellon
14
Bank of New York Mellon
New York
$47K – – –
RCM
15
Rotella Capital Management
Washington
$36K +$28.5K +23 New
CCB
16
Cutter & Co Brokerage
Missouri
$33K -$4.95K -4 -16%
PNC Financial Services Group
17
PNC Financial Services Group
Pennsylvania
$27K – – –
Nomura Holdings
18
Nomura Holdings
Japan
$23K +$22.3K +18 New
Royal Bank of Canada
19
Royal Bank of Canada
Ontario, Canada
$8K +$2.48K +2 +67%
Wells Fargo
20
Wells Fargo
California
$3K – – –
BI
21
BVF Inc
California
– -$3.17M -2,502 Closed
SM
22
Sabby Management
Florida
– -$1.57M -1,241 Closed
SFM
23
Sphera Funds Management
Israel
– -$408K -322 Closed
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
– -$145K -115 Closed
Jane Street
25
Jane Street
New York
– -$39K -30 Closed
1
2

BLRX Hedge Fund Activity: Q2 2015 in Review

20 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2015, worth a combined $29.3M — up 8.7% from $26.9M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of BLRX and 3 opened new positions — a net loss of 5 holders — while 3 trimmed existing stakes and 6 added.

The largest buyer was Senvest Management, adding an estimated $669K. The largest seller was BVF Inc, exiting entirely with an estimated $3.17M sold.

  • 20 institutional investors held BioLineRX (BLRX) as of Q2 2015, down from 25 in Q1 2015.
  • Funds reported $29.3M of BioLineRX stock for Q2 2015, up 8.7% quarter-over-quarter.
  • 3 funds opened new BioLineRX positions in Q2 2015 and 8 closed out, a net change of -5 holders.
  • The largest BioLineRX buyer in Q2 2015 was Senvest Management, an estimated $669K added.
  • The largest BioLineRX seller in Q2 2015 was BVF Inc, an estimated $3.17M sold.

Based on aggregated 13F filings for Q2 2015.